Research Analysts’ Recent Ratings Updates for Amicus Therapeutics (FOLD)

Several brokerages have updated their recommendations and price targets on shares of Amicus Therapeutics (NASDAQ: FOLD) in the last few weeks:

• 12/18/2024 – Amicus Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 12/13/2024 – Amicus Therapeutics had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $12.00 price target on the stock, down previously from $17.00.
• 12/10/2024 – Amicus Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 12/2/2024 – Amicus Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/16/2024 – Amicus Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/12/2024 – Amicus Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $17.00. They now have an “overweight” rating on the stock.
• 11/8/2024 – Amicus Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/7/2024 – Amicus Therapeutics had its price target raised by analysts at Cantor Fitzgerald from $20.00 to $21.00. They now have an “overweight” rating on the stock.
• 11/7/2024 – Amicus Therapeutics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 11/7/2024 – Amicus Therapeutics had its price target raised by analysts at Guggenheim from $13.00 to $15.00. They now have a “buy” rating on the stock.
• 10/31/2024 – Amicus Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 10/23/2024 – Amicus Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

Amicus Therapeutics Price Performance

FOLD traded down $0.01 on Wednesday, reaching $9.88. The company had a trading volume of 152,855 shares, compared to its average volume of 2,708,937. The company has a fifty day moving average of $10.51 and a 200-day moving average of $10.62. The company has a market capitalization of $2.95 billion, a P/E ratio of -29.06 and a beta of 0.60. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $11.46, for a total transaction of $85,950.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,161,054.84. The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 30,401 shares of company stock worth $339,363. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OLD Second National Bank of Aurora acquired a new stake in Amicus Therapeutics during the 3rd quarter worth about $26,000. Hazlett Burt & Watson Inc. lifted its position in shares of Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,569 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new position in Amicus Therapeutics during the third quarter valued at approximately $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Amicus Therapeutics in the 3rd quarter valued at approximately $55,000.

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.